We co-treated breast cancer cells MDA-MB-231 (with high LOXL1 and BAG2 expression) with HSP90 inhibitor (IPI-504), HSP70 inhibitor (VER-155008), LOX inhibitor (BAPN), or NAMPT (FK886) inhibitor and doxorubicin, and we observed the survival rate to calculate the drug interactions. Here, LOXL1 is linked to breast carcinoma.